Eurogin is part of the Informa Markets Division of Informa PLC

Informa
Informa

Preliminary Program is live!

HPV and Head & Neck Forum

Thursday, February 9
14.00 • 19.00

Friday, February 10
8.00 • 16.00

Coordinators:
K. Lang Kuhs (USA) • J. P. Klussmann (Germany) • H. Mirghani (France) • E. Rettig (USA)

The EUROGIN HPV and Head & Neck Cancer Forum highlights recent advances and areas of active research in the field of HPV-related head and neck cancers. This year’s Forum features talks on epidemiology and prevention, HPV-OPC screening studies, updates on current management, innovations in surveillance and new discoveries of the molecular landscape of HPV-OPC tumors. New for this year, the Forum will also feature several panel discussions exploring the potential promise and peril of screening, surgery versus chemoradiation therapy and risks versus benefit of using liquid biopsy for HPV-OPC surveillance.

Thursday, February 9

14.00 - 15.30

Screening for HPV-OPC

Chair: K. Lang Kuhs (USA) • T. Waterboer (Germany)

Updates on 2 US-based HPV-OPC screening studies

K. Lang Kuhs (USA)

Prevalence of HPV biomarkers among screened populations

A. D’Souza (USA)

Biomarker-based screening trial updates

T. Waterboer (Germany)

Modeling serologic screening for HPV-OPC

H. Robbins (France)

Prediagnostic liquid biopsy

D. Faden (USA)

PANEL: Pros vs. Cons of screening for HPV-OPC

E. Sturgis (USA)
vs. K. Lang Kuhs (USA)

15.30 - 16.00

Coffee Break

16.00 - 17.30

Basic science

Chair: S. Virani (France)

Recurrent Respiratory Papillomatosis: Updates

S. Pransky (USA)

HPV therapeutic vaccine trials

A. Kejner (USA)

Cell plasticity in HPV-driven tumors

J. Hess (Germany)

Single cell sequencing in HPV-OPC

S. Puram (USA)

Granular stratification of OPC patients using standard H&E staining

S. Klein (Germany)

Evaluation of HPV genome integration

E. J. Speel (Netherlands)

Germline Genetics for risk of HPV-driven head and neck cancers

S. Virani (France)

17.30 - 19.00

Submitted papers

Chair: K. Van Able (USA)

Friday, February 10

8.00 - 9.30

Epidemiology and prevention of HPV-OPC

Chair: E. Rettig (USA)

HPV-OPC incidence trends

A. Deshmukh (USA)

Oral HPV infection and HIV

N. Osazuwa-Peters (USA)

Impact of tonsillectomy on risk of HPV-OPC 

J. D. Combes (France)

HPV vaccination for prevention of oral HPV infection

A. Giuliano (USA)

What should be communicated to women with oncogenic genital HPV and their partners regarding the risk of oral viral transmission

G. Barbara (Italy)

Patient priorities and concerns

M. Windon (USA)

9.30 - 10.00

Coffee Break

10.00 - 11.30

Management

Chair: H. Mirghani (France)

Outcomes beyond survival

H. Starmer (USA)

Aggressive adjuvant radiation reduction after surgery for HPV-OPC

D. Routman (USA)

ORATOR trials

M. Patel (USA)

Overview of De-escalation strategies and potential of genomics for prediction

M. Lechner (UK)

Neoadjuvant immunotherapy pre-CRT in HPV-OPC

H. Mirghani (France)

PANEL: Surgery versus CRT for HPV-OPC

C. Simon (Switzerland)
vs. R. Haddad (USA) 

11.30 - 13.15

Lunch Break

13.15 - 14.30

Submitted papers

Chair: J. Hess (Germany)

14.30 - 16.00

Molecular diagnosis and surveillance

Chair: J. P. Klussmann (Germany)

Prognostic implication of p16/HPV discordance

L. Alemany (Spain)

Cell-free HPV DNA in urine

C. Brenner (USA)

TTMV-HPV DNA for surveillance in the clinic

E. Rettig (USA)

ctHPV-DNA: Techniques and their clinical utility

N. Würdemann (Germany)

Randomized controlled trial of standard vs. liquid biopsy-based surveillance

H. Mirghani (France)

PANEL: Pros vs. Cons of liquid biopsy for surveillance

L. Mady (USA)
vs. G. Hanna (USA)